Investment
Features
FeesSafety
Academy
More
Pluang+

Compare United States Copper Index Fund (CPER) vs Eli Lilly And Co (LLY) Price & Performance

United States Copper Index FundTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

United States Copper Index Fund vs Eli Lilly And Co — how do they compare? United States Copper Index Fund trades at $40.73, while Eli Lilly And Co trades at $1,214.9 (market cap $1.10T). The key difference: Eli Lilly And Co pays a 0.56% dividend while United States Copper Index Fund pays none. Which is the better fit depends on your goals.

CPERLLY
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$40.85$1.24K
52-Week Low
$27.57$639.43
Market Cap
$1.10T
Enterprise Value
$1.14T
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

United States Copper Index Fund

CPER, the United States Copper Index Fund, trades at $39.9, down 2.11% today, amid a broader bullish technical signal driven by moving averages. Recent news highlights record copper prices fueled by supply disruptions and strong demand from electrification and AI infrastructure. Key support sits at $39, with resistance at $41. Financial ratios are not applicable as this is an ETF tracking copper futures.

The outlook for CPER is positive, supported by structural copper demand trends, but carries risks from potential supply normalization and commodity price volatility. Investors gain exposure to copper's price movements without direct company fundamentals, making it a pure play on industrial metal trends influenced by global economic conditions.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About United States Copper Index Fund

CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.

Read more on CPER

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY